Inovio dMAb™ constructs shrink prostate tumors against antibiotic-resistant infection
Inovio announced that the development of its DNA-based monoclonal antibody program received a boost from two peer-reviewed scientific papers that demonstrate their impact on prostate tumors and in preventing infection from a pneumonia-causing bacteria in preclinical studies.
September 21, 2017